[Tyr1] -pTH (1-34), human

pTH (1-34) (human) corresponds to N-terminal part of human parathyroid hormone, a peptide consisting of 84 amino acids. pTH (1-34) (human) shows the same activity and pharmacological profile as the native peptide hormone. Intermittent administration of pTH (1-34) (human) acetate in low dosage stimulates bone formation and increases bone mineral density. Lifetein's pTH (1-34) (human) is obtained by chemical synthesis.

[Tyr1] -pTH (1-34), human is a 34-residue synthetic peptide with the sequence Tyr-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe. The sequence contains 3 Lys and 2 Arg residues, contributing cationic character; contains 3 aromatic residues that can contribute to hydrophobic or aromatic interactions. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence.

• LC-MS/HPLC analytical method development
• sequence-specific assay controls

Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions.